In vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative radiotherapy as boost

Jason Joon Bock Lee, Jinhyun Choi, Sung Gwe Ahn, Jeong Joon, Ik Jae Lee, Kwangwoo Park, Kangpyo Kim, Jun Won Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Purpose: To report the results of a correlation analysis of skin dose assessed by in vivo dosimetry and the incidence of acute toxicity. This is a phase 2 trial evaluating the feasibility of intraoperative radiotherapy (IORT) as a boost for breast cancer patients. Materials and Methods: Eligible patients were treated with IORT of 20 Gy followed by whole breast irradiation (WBI) of 46 Gy. A total of 55 patients with a minimum follow-up of 1 month after WBI were evaluated. Optically stimulated luminescence dosimeter (OSLD) detected radiation dose delivered to the skin during IORT. Acute toxicity was recorded according to the Common Terminology Criteria for Adverse Events v4.0. Clinical parameters were correlated with seroma formation and maximum skin dose. Results: Median follow-up after IORT was 25.9 weeks (range, 12.7 to 50.3 weeks). Prior to WBI, only one patient developed acute toxicity. Following WBI, 30 patients experienced grade 1 skin toxicity and three patients had grade 2 skin toxicity. Skin dose during IORT exceeded 5 Gy in two patients: with grade 2 complications around the surgical scar in one patient who received 8.42 Gy. Breast volume on preoperative images (p = 0.001), ratio of applicator diameter and breast volume (p = 0.002), and distance between skin and tumor (p = 0.003) showed significant correlations with maximum skin dose. Conclusions: IORT as a boost was well-tolerated among Korean women without severe acute complication. In vivo dosimetry with OSLD can help ensure safe delivery of IORT as a boost.

Original languageEnglish
Pages (from-to)121-128
Number of pages8
JournalRadiation Oncology Journal
Volume35
Issue number2
DOIs
Publication statusPublished - 2017 Jan 1

Fingerprint

Radiotherapy
Breast Neoplasms
Skin
Breast
Luminescence
Seroma
In Vivo Dosimetry
Terminology
Cicatrix
Incidence
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Lee, Jason Joon Bock ; Choi, Jinhyun ; Ahn, Sung Gwe ; Joon, Jeong ; Lee, Ik Jae ; Park, Kwangwoo ; Kim, Kangpyo ; Kim, Jun Won. / In vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative radiotherapy as boost. In: Radiation Oncology Journal. 2017 ; Vol. 35, No. 2. pp. 121-128.
@article{f39b7ebfc19e48c89c9ea11a474a6b7c,
title = "In vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative radiotherapy as boost",
abstract = "Purpose: To report the results of a correlation analysis of skin dose assessed by in vivo dosimetry and the incidence of acute toxicity. This is a phase 2 trial evaluating the feasibility of intraoperative radiotherapy (IORT) as a boost for breast cancer patients. Materials and Methods: Eligible patients were treated with IORT of 20 Gy followed by whole breast irradiation (WBI) of 46 Gy. A total of 55 patients with a minimum follow-up of 1 month after WBI were evaluated. Optically stimulated luminescence dosimeter (OSLD) detected radiation dose delivered to the skin during IORT. Acute toxicity was recorded according to the Common Terminology Criteria for Adverse Events v4.0. Clinical parameters were correlated with seroma formation and maximum skin dose. Results: Median follow-up after IORT was 25.9 weeks (range, 12.7 to 50.3 weeks). Prior to WBI, only one patient developed acute toxicity. Following WBI, 30 patients experienced grade 1 skin toxicity and three patients had grade 2 skin toxicity. Skin dose during IORT exceeded 5 Gy in two patients: with grade 2 complications around the surgical scar in one patient who received 8.42 Gy. Breast volume on preoperative images (p = 0.001), ratio of applicator diameter and breast volume (p = 0.002), and distance between skin and tumor (p = 0.003) showed significant correlations with maximum skin dose. Conclusions: IORT as a boost was well-tolerated among Korean women without severe acute complication. In vivo dosimetry with OSLD can help ensure safe delivery of IORT as a boost.",
author = "Lee, {Jason Joon Bock} and Jinhyun Choi and Ahn, {Sung Gwe} and Jeong Joon and Lee, {Ik Jae} and Kwangwoo Park and Kangpyo Kim and Kim, {Jun Won}",
year = "2017",
month = "1",
day = "1",
doi = "10.3857/roj.2017.00150",
language = "English",
volume = "35",
pages = "121--128",
journal = "Radiation Oncology Journal",
issn = "2234-1900",
publisher = "Korean Society for Therapeutic Radiology and Oncology",
number = "2",

}

In vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative radiotherapy as boost. / Lee, Jason Joon Bock; Choi, Jinhyun; Ahn, Sung Gwe; Joon, Jeong; Lee, Ik Jae; Park, Kwangwoo; Kim, Kangpyo; Kim, Jun Won.

In: Radiation Oncology Journal, Vol. 35, No. 2, 01.01.2017, p. 121-128.

Research output: Contribution to journalArticle

TY - JOUR

T1 - In vivo dosimetry and acute toxicity in breast cancer patients undergoing intraoperative radiotherapy as boost

AU - Lee, Jason Joon Bock

AU - Choi, Jinhyun

AU - Ahn, Sung Gwe

AU - Joon, Jeong

AU - Lee, Ik Jae

AU - Park, Kwangwoo

AU - Kim, Kangpyo

AU - Kim, Jun Won

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Purpose: To report the results of a correlation analysis of skin dose assessed by in vivo dosimetry and the incidence of acute toxicity. This is a phase 2 trial evaluating the feasibility of intraoperative radiotherapy (IORT) as a boost for breast cancer patients. Materials and Methods: Eligible patients were treated with IORT of 20 Gy followed by whole breast irradiation (WBI) of 46 Gy. A total of 55 patients with a minimum follow-up of 1 month after WBI were evaluated. Optically stimulated luminescence dosimeter (OSLD) detected radiation dose delivered to the skin during IORT. Acute toxicity was recorded according to the Common Terminology Criteria for Adverse Events v4.0. Clinical parameters were correlated with seroma formation and maximum skin dose. Results: Median follow-up after IORT was 25.9 weeks (range, 12.7 to 50.3 weeks). Prior to WBI, only one patient developed acute toxicity. Following WBI, 30 patients experienced grade 1 skin toxicity and three patients had grade 2 skin toxicity. Skin dose during IORT exceeded 5 Gy in two patients: with grade 2 complications around the surgical scar in one patient who received 8.42 Gy. Breast volume on preoperative images (p = 0.001), ratio of applicator diameter and breast volume (p = 0.002), and distance between skin and tumor (p = 0.003) showed significant correlations with maximum skin dose. Conclusions: IORT as a boost was well-tolerated among Korean women without severe acute complication. In vivo dosimetry with OSLD can help ensure safe delivery of IORT as a boost.

AB - Purpose: To report the results of a correlation analysis of skin dose assessed by in vivo dosimetry and the incidence of acute toxicity. This is a phase 2 trial evaluating the feasibility of intraoperative radiotherapy (IORT) as a boost for breast cancer patients. Materials and Methods: Eligible patients were treated with IORT of 20 Gy followed by whole breast irradiation (WBI) of 46 Gy. A total of 55 patients with a minimum follow-up of 1 month after WBI were evaluated. Optically stimulated luminescence dosimeter (OSLD) detected radiation dose delivered to the skin during IORT. Acute toxicity was recorded according to the Common Terminology Criteria for Adverse Events v4.0. Clinical parameters were correlated with seroma formation and maximum skin dose. Results: Median follow-up after IORT was 25.9 weeks (range, 12.7 to 50.3 weeks). Prior to WBI, only one patient developed acute toxicity. Following WBI, 30 patients experienced grade 1 skin toxicity and three patients had grade 2 skin toxicity. Skin dose during IORT exceeded 5 Gy in two patients: with grade 2 complications around the surgical scar in one patient who received 8.42 Gy. Breast volume on preoperative images (p = 0.001), ratio of applicator diameter and breast volume (p = 0.002), and distance between skin and tumor (p = 0.003) showed significant correlations with maximum skin dose. Conclusions: IORT as a boost was well-tolerated among Korean women without severe acute complication. In vivo dosimetry with OSLD can help ensure safe delivery of IORT as a boost.

UR - http://www.scopus.com/inward/record.url?scp=85021843633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021843633&partnerID=8YFLogxK

U2 - 10.3857/roj.2017.00150

DO - 10.3857/roj.2017.00150

M3 - Article

VL - 35

SP - 121

EP - 128

JO - Radiation Oncology Journal

JF - Radiation Oncology Journal

SN - 2234-1900

IS - 2

ER -